ERGOMED

News

London, UK, 12 May 2017

Annual Report and Notice of AGM

London, UK – 12 May 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that it will hold its Annual General Meeting at the offices of Covington & Burling LLP, 265…


London, UK, 08 May 2017

Ergomed Issues First Earn-Out Shares to Former Shareholders of PharmInvent

London, UK – 8 May 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, today announces that the conditions for the issue of 94,618 additional new ordinary shares of 1p each in the Company to…


London, UK, 02 May 2017

Ergomed notes announcement by co-development partner, Aeterna Zentaris, of results from Phase 3 clinical trial with Zoptrex™ in advanced endometrial cancer

London, UK – 02 May 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, notes that its co-development partner Aeterna Zentaris has announced that its Pivotal Phase 3 Clinical Trial of Zoptrex™ in…


London, UK, 13 April 2017

Board and Management Changes

London, UK – 13 April 2017: Ergomed plc (LSE: ERGO) (‘Ergomed’ or ‘the Company’), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces Board and management changes.

Neil Clark will step down as a Director of Ergomed plc with effect…


London, UK, 4 April 2017

Ergomed PLC Director Dealing

Ergomed, a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that on 3 April 2017, Mr Peter George, Chairman of the Company, bought 100,000 ordinary shares of 1p each in the Company (“Share(s)”) at a price of 190p per Share. Following this…


Page 4 of 19« First...23456...10...Last »
Translate »